Capitalizing on Europe’s research connections to tackle cancer

• The EU-backed canSERV initiative provides cancer researchers and biotech firms across Europe with centralized access to specialized facilities, data, and advanced analytical tools.
• By linking resources from nine EU countries and the UK, the platform aims to overcome the traditional fragmentation of the European oncology research landscape.
• Over 150 researchers from 25 countries have utilized the platform to date, with operations currently scheduled to run through August 2026.

Overcoming Research Fragmentation

• European cancer research often suffers from isolated networks and limited access to shared data or infrastructure.
• canSERV acts as a "virtual European core facility," allowing researchers to request and access specific services—such as DNA sequencing or AI-assisted analysis—from partner institutions.
• The initiative reduces barriers for both academic labs, such as Masaryk University in Czechia, and private biotech companies.

Supporting Innovation and Biotech

• Barcelona-based Aptadel Therapeutics used canSERV to conduct multiomics analyses, integrating genomic and protein data to refine RNA-based cancer treatments.
• The partnership enabled the company to visualize tumor cell molecular changes over time, aiding in the development of more effective and less toxic therapies.
• Participants intend to share generated datasets with the broader scientific community to accelerate collective progress.

Strategic Goals

• Professor Jens Habermann of BBMRI-ERIC, which leads the collaboration, compares the initiative to shared transport infrastructure, essential for connecting fragmented "airports" of research.
• The program seeks to level the playing field by ensuring that high-level research services are available to scientists regardless of their region's specific capabilities.